Login to Your Account

Astellas Halts Phase II of XenoPort Pain Drug

By Donna Young

Friday, November 7, 2008
XenoPort Inc. said its Japanese partner Astellas Pharma Inc. terminated a Phase II study of XP13512, a transported prodrug of gabapentin, in patients with painful diabetic neuropathy (PDN) after an analysis showed it was unlikely the trial would reach statistical significance. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription